Last reviewed · How we verify
Prevention of venous thromboembolism from re-occuring
Approved treatments
- Xarelto · University Hospital, Montpellier
- Xarelto · Johnson & Johnson
Selective FXa inhibitor that decreases thrombin generation without requiring cofactors.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of venous thromboembolism from re-occuring patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of venous thromboembolism from re-occuring treatment landscape brief
- Prevention of venous thromboembolism from re-occuring treatment updates RSS
Frequently asked questions about Prevention of venous thromboembolism from re-occuring
What drugs treat Prevention of venous thromboembolism from re-occuring?
Tracked treatments include Xarelto.
What is the treatment for Prevention of venous thromboembolism from re-occuring?
Standard treatment for Prevention of venous thromboembolism from re-occuring includes Xarelto. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of venous thromboembolism from re-occuring patent cliff · Prevention of venous thromboembolism from re-occuring CI report
- Treatment: Xarelto · University Hospital, Montpellier
- Treatment: Xarelto · Johnson & Johnson
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing